This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Progenics' AI-based cancer diagnostic patents survive US eligibility challenge

By Melissa Ritti ( January 15, 2025, 17:09 GMT | Insight) -- A Massachusetts federal judge yesterday refused to dismiss allegations MIM Software infringes four Progenics Pharmaceuticals patents which claim, among other things, a neural network-based method for determining the uptake of radiopharmaceuticals and the use of artificial intelligence to detect and characterize lesions. Although two other patents were deemed noninfringed, the ruling marks a win for critics of current US patent eligibility jurisprudence in the AI era.A bid by MIM Software for an early win on allegations it infringes a series of Progenics Pharmaceuticals’ patents was largely thwarted yesterday when a US court said a subset of the claimed systems for improving the diagnosis of cancer and other diseases pass muster under Section 101 of the Patent Act....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login